Isolation and characterization of contaminants in recalled unfractionated heparin and low-molecular-weight heparin

Clinical and Applied Thrombosis/Hemostasis

Volumn 15, Issue 4, 2009, Pages 395-401

  Viskov, Christian ^c   Bouley, E ^a   Hubert, P ^a   Martinez, Celine ^a   Herman, F ^a   Jeske, Walter ^b   Hoppensteadt, Debra ^b   Walenga, Jeanine M ^b   Fareed, Jawed ^b  

^a SANOFI   (France)

^b LOYOLA UNIVERSITY CHICAGO   (United States)

^c NONE   (France)

Author keywords

Heparin; Low molecular weight heparin; Oversulfated chondroitin sulfate

Indexed keywords

CHONDROITIN 4 SULFATE; CHONDROITIN 6 SULFATE; CHONDROITIN SULFATE; DERMATAN SULFATE; ENOXAPARIN; HEPARIN; HEPARIN LYASE;

ARTICLE; DRUG CONTAMINATION; DRUG ISOLATION; ENZYME DEGRADATION; GEL PERMEATION CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE;

ANIMALS; ANTICOAGULANTS; CHONDROITIN ABC LYASE; CHONDROITIN SULFATES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG CONTAMINATION; ENOXAPARIN; HEPARIN LYASE; HEPARIN, LOW-MOLECULAR-WEIGHT; METHANOL; MOLECULAR WEIGHT; NITROUS ACID; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; OLIGOSACCHARIDES; SHARKS; SWINE;

EID: 69749122095     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/1076029609338710     Document Type: Article

References (17)

1. Hirsh J., Raschke R. Heparin and low-molecular-weight heparin. Chest. 2004 ; 126 (suppl 3). 188S - 203S.
2. Jeske WP, Walenga JM, Hoppensteadt DA, et al. Differentiating low-molecular-weight heparins based on chemical, biological and pharmacologic properties: implications for the development of generic versions of low-molecular-weight heparins. Semin Thromb Hemost. 2008 ; 34 (1). 74-85.
3. Becker RC New thrombolytic, anticoagulants and platelet antagonists: The future of clinical practice. J Thromb Thrombolysis. 1999 ; 7 (2). 195-220.
4. Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation. 1999 ; 100 (15). 1593-1601.
5. Cohen M., Demers C., Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med. 1997 ; 337 (7). 447-452.
6. Centers for Disease Control and Prevention (CDC). Acute allergic-type reactions among patients undergoing hemodialysis-multiple states, 2007-2008. MMWR Morb Mortal Wkly Rep. 2008 ; 57 (5). 124-125.
7. US Food and Drug Administration. Information on adverse events and heparin. Volume 2009 ; 2008. http://www.fda.gov/cder/drug/infopage/heparin/ adverse-events.htm. Retrieved on March 6, 2009.
8. Guerrini M., Beccati D., Shriver Z., et al. Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events. Nat Biotechnol. 2008 ; 26 (6). 669-675. (Pubitemid 351824692)
9. Kishimoto TK, Viswanathan K., Ganguly T., et al. Contaminated heparin associated with adverse clinical events and activation of the contact system. N Eng J Med. 2008 ; 358 (23). 2457-2467.
10. Ahsan A., Jeske W., Hoppensteadt D., Lormeau JC, Wolf H., Fareed J. Molecular profiling and weight determination of heparins and depolymerized heparins. J Pharm Sci. 1995 ; 84 (6). 724-727.
11. Maruyama T., Toida T., Imanari T., Yu G., Linhardt RJ Conformational changes and anticoagulant activity of chondroitin sulfate following its O-sulfonation. Carbohydr Res. 1998 ; 306 (1-2). 35-43.
12. Denti A., Sini P., Tira ME, Balduini C. Structural heterogeneity of dermatan sulfate chains: correlation with heparin cofactor II activating properties. Thromb Res. 1995 ; 79 (2). 187-198.
13. Sandset PM, Abildgaard P., Larsen ML Heparin induces release of extrinsic pathway inhibitor (EPI). Thromb Res. 1988 ; 50 (6). 803-813.
14. Fareed J., Walenga JM, Jeske WP, et al. Biological profile of the hyper/oversulfated chondroitin sulfate contaminant isolated from recalled heparin. Semin Thromb Hemost. 2008 ; 34 (suppl 1). 119-127.
15. Debrie R., Rhone-Poulenc Rorer SA (assignee). Mixtures of particular LMW heparinic polysaccharides for the prophylaxis/treatment of acute thrombotic events. USA patent 5, 389, 618. 1995.
16. Zhang Z., Weiwer M., Li B., Kemp MM, Daman TH, Linhardt RJ Oversulfated chondroitin sulfate: impact of a heparin impurity, associated with adverse clinical events, on low-molecular-weight heparin preparation. J Med Chem. 2008 ; 51 (18). 5498-5501.
17. Bienkowski MJ, Conrad HE Structural characterization of the oligosaccharides formed by depolymerization of heparin with nitrous acid. J Biol Chem. 1985 ; 260 (1). 356-365.